And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our signal to daydream about weekend plans. Our agenda is rather modest. We hope to spend time with a couple of our short people, engage the official mascots, and catch up on our reading. And what about you? Summer is nearing an end, so perhaps you can take one last jaunt to the ocean or lake. You could also prepare for autumn and purchase a sweater or rake. Or you could check to see if anyone has written any anonymous missives about you. Well, whatever you do, have a grand time. But be safe. By the way, we will be gone until Wednesday while we observe ancient traditions. A colleague will forward the newsletter to you in our absence. Meanwhile, enjoy …

Trump administration restrictions on hiring those who have lived outside of the U.S. is making it difficult for the Food and Drug Administration to attract top talent, STAT writes. The policy “definitely has created an additional challenge, I think, for us. The U.S. just doesn’t graduate the number that we need to fill our vacancies,” says Melanie Keller, acting associate commissioner for scientific and clinical recruitment. The agency must restrict the number of offers of employment they make to people who have lived outside the U.S. for three of the past five years.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Unless this patent was filed simultaneously with the one for Oxycontin, I find the ‘moral outrage’ pedantic at best. “The idea Sackler “could get richer” from the patent was “very disturbing,” says Andrew Kolodny…”
    Next some will say it’s disturbing for the head of HHS to have worked for Lilly for many years … oh, wait!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy